TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AZN

AstraZeneca PLC Ordinary Shares

NYSE
$174.35
▲ $5.53 (+3.3%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $196.41L $153.41-4.0%
$196.41$187.81$179.21$170.61$162.01$153.41$174.35
RSI (14)
Intraday · 15-minSell-35RSI 33DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Neutral+10
RSI (14)44
oversold 30overbought 70
Trend
Uptrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
above
vs 200-day
below
Support
$167.96
Resistance
$192.65
  • Price is above its 50-day average (medium-term uptrend).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
-12.7%
Buy & hold
-14.6%
Trades
5
Win rate
0%

$100,000.00 invested would be worth $87,331.05 (-12.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AstraZeneca PLC· Drug Manufacturers - General

source: yahoo

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
96,100
Headquarters

Fundamentals

source: yahoo
Market cap
$270.4B
P/E
24.7
P/B
5.2
EPS
$7.07
Div yield
1.8%
Profit margin
17.7%
ROE
22.6%
Debt / Equity
0.66
Beta
0.15
52-week range
$153.41 – $212.71
52-week low · $153.4135% of rangehigh · $212.71

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive2↑ · 1↓ · 5–
  • AstraZeneca leads European big pharma on growth, pipeline depth▲ Positive
    Investing.com · 20 Nov 2026
  • FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug— Neutral
    Zacks · 20 Nov 2026
  • Oncology Clinical Trials - Global Strategic Business Report 2026: Secure Share of a $6 Billion Revenue Surge by 2032 as AbbVie, AstraZeneca, ICON, Merck, and Roche Accelerate AI-Led Trials▲ Positive
    GlobeNewswire · 20 Nov 2026
  • Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Cambridge, United Kingdom
www.astrazeneca.com ↗
— Neutral
Reuters · 20 Nov 2026
  • European shares tumble again as Anthropic debut fails to halt tech rout▼ Negative
    Investing.com · 20 Nov 2026
  • Why AstraZeneca Could Make Sense Through ETFs Now— Neutral
    Simply Wall St. · 19 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.